Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523520 · ClinicalTrials.gov registry record · Phase 4
Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation
A Phase 4 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03523520: Completed Phase 4 study, sponsored by University of Missouri-Columbia.
NCT03523520 is a Phase 4 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03523520, a Phase 4 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
Primary Outcome
The primary outcome of this study is to determine the effectiveness of peripherally acting mu-opioid receptor antagonist therapy for patients presenting to the emergency department (ED) with opioid-induced constipation.
Interventions
- DRUG Methylnaltrexone Bromide 150 mg Oral Tablet
- DRUG Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1
- DRUG Naloxegol 25 MG Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-12-23 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 4 |
What the finished NCT03523520 record still lists
NCT03523520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Methylnaltrexone Bromide 150 mg Oral Tablet is the first listed.
NCT03523520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03523520 about?
NCT03523520 is a clinical study titled "Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation". The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
What is the current status of trial NCT03523520?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2020-12-23. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT03523520?
The interventions under investigation include: Methylnaltrexone Bromide 150 mg Oral Tablet (DRUG), Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1 (DRUG), Naloxegol 25 MG Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03523520?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03523520's enrollment target sits among peer trials
15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI